Investing.com - DexCom (NASDAQ: DXCM) reported fourth quarter EPS of $0.50, $0.07 better than the analyst estimate of $0.43. Revenue for the quarter came in at $1.03B versus the consensus estimate of $1.02B.
Guidance
DexCom sees FY 2024 revenue of $4.15B-$4.35B versus the analyst consensus of $4.33B.
DexCom's stock price closed at $127.05. It is up 35.09% in the last 3 months and up 18.47% in the last 12 months.
DexCom saw 9 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See DexCom's stock price’s past reactions to earnings here.
According to InvestingPro, DexCom's Financial Health score is "great performance".
Check out DexCom's recent earnings performance, and DexCom's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar